See Full Prescribing Details OPDIVO® (nivolumab) is indicated with the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed just after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or after 3 or maybe more lines of systemic therapy that features autologous HSCT.T